• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

InSite Vision to Announce 2nd Quarter 2007 Financial Results and Hold Conference Call on August 8, 2007

Posted on: Wednesday, 1 August 2007, 09:06 CDT

InSite Vision Incorporated (AMEX:ISV), an ophthalmic therapeutics, diagnostics and drug delivery company, announced today that the company will release 2007 second quarter results on Wednesday, August 8, 2007.

Kumar Chandrasekaran, Ph.D., chief executive officer, will host a conference call beginning at 5:00 p.m. EDT on Wednesday, August 8, 2007 to discuss these results.

Analysts and investors interested in listening to the conference call may do so by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will have to enter the account number 286 and conference ID 249189.

The live conference call will also be webcast and available at www.InvestorCalendar.com as well as the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following completion of the conference call. In addition, the Company's second quarter earnings release will be posted to the Company's web site and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above.

About InSite Vision Incorporated

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite™, a topical anti-infective which targets infections of the eye, approved by the FDA in April 2007. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite®, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen that is attractive to both the eye-care patient and physician.

Inspire Pharmaceuticals (NASDAQ:ISPH) has the responsibility to commercialize AzaSite in the U.S. and Canada in accordance with the parties' out-license agreement. InSite plans to pursue additional commercial partnerships during 2007 to address AzaSite market opportunities outside the U.S. and Canada.

Based on InSite Vision's proprietary DuraSite drug delivery technology, the Company is developing additional anti-infective therapies, including AzaSite Plus, an antibiotic and corticosteroid combination product candidate that has completed Phase 1 trials, in which the antibiotic inhibits ocular bacterial proliferation while the corticosteroid allows suppression of the inflammatory response; AzaSite Otic, a product candidate in the AzaSite family currently under development for the treatment of bacterial ear infections; and AzaSite Xtra, a product candidate in the AzaSite family currently under development for the treatment of ocular infection.

This news release contains certain statements of a forward-looking nature relating to future events, such as the timing of the anticipated commercialization of AzaSite, the expected benefits of AzaSite, the company's plans to seek additional corporate collaborations to expand AzaSite outside the U.S. and Canada, the proposed indications and clinical status of the Company's other product candidates, and the proposed timing of the Company's release of second quarter 2007 financial results. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional funding to continue its operations; its reliance on third parties, including Inspire, for the commercialization of AzaSite and its other products; the ability of InSite Vision to enter into a corporate collaboration for AzaSite outside the U.S. and Canada and with respect to its other product candidates; the ability to commercially launch AzaSite and the timing and success of such a launch; InSite Vision's ability to expand its technology platform to include additional indications; market acceptance of AzaSite; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; and its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; determinations by the FDA, including those with respect to AzaSite Plus and ISV-205, and possible delays in InSite Vision's release of its second quarter 2007 financial results. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.

Source: Business Wire

More News in this Category